Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cisbio Bioassays currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit. The company's current USPTO activity is focused on a single point of examination. This concentration allows for a streamlined prosecution strategy that targets the specific requirements of the biotechnological field.
IVICH, FERNANDO NMN is the busiest examiner for the portfolio, handling 1 pending office action. This represents the total pending workload for the company. Because the prosecution is limited to 1 examiner and 1 art unit, the strategy should be tailored to the specific examination style of this individual. Practitioners should focus on the procedural standards of the 1 distinct art unit to ensure a smooth review process.
The presence of only 1 pending office action means that the company's patent success is currently tied to the outcome of this single matter. There is no internal baseline for comparison across different examiners or art units. Practitioners should monitor the typical response times for IVICH, FERNANDO NMN within the Biotechnology & Pharmaceuticals technology area to set realistic expectations for the company's patent trajectory.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IVICH, FERNANDO NMN | 1 | 52.4% | +72.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18290265 | METHOD FOR DETERMINING THE BINDING OF AN ANTIBODY TO THE COMPLEMENT COMPONENT IQ (CIQ) | IVICH, FERNANDO NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18290265 | METHOD FOR DETERMINING THE BINDING OF AN ANTIBODY TO THE COMPLEMENT COMPONENT IQ (CIQ) | IVICH, FERNANDO NMN | — |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18290265 | METHOD FOR DETERMINING THE BINDING OF AN ANTIBODY TO THE COMPLEMENT COMPONENT IQ (CIQ) | IVICH, FERNANDO NMN | 1678 | §102§103§112Other | Non-Final OA | — | Pending | Nov 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCisbio Bioassays has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Fernando Nmn Ivich has the most, with 1 of Cisbio Bioassays's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
